1. Home
  2. WALD vs CRBP Comparison

WALD vs CRBP Comparison

Compare WALD & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Waldencast plc

WALD

Waldencast plc

HOLD

Current Price

$1.29

Market Cap

187.3M

ML Signal

HOLD

Logo Corbus Pharmaceuticals Holdings Inc.

CRBP

Corbus Pharmaceuticals Holdings Inc.

HOLD

Current Price

$9.85

Market Cap

168.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WALD
CRBP
Founded
1988
2009
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Package Goods/Cosmetics
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
187.3M
168.3M
IPO Year
2021
2014

Fundamental Metrics

Financial Performance
Metric
WALD
CRBP
Price
$1.29
$9.85
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
6
Target Price
$2.00
$45.50
AVG Volume (30 Days)
305.3K
336.1K
Earning Date
03-13-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$4,822,272.00
Revenue This Year
$9.89
N/A
Revenue Next Year
$4.31
$116.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
97.62
52 Week Low
$0.72
$7.12
52 Week High
$3.22
$20.56

Technical Indicators

Market Signals
Indicator
WALD
CRBP
Relative Strength Index (RSI) 33.36 54.85
Support Level $1.23 $9.50
Resistance Level $1.85 $10.74
Average True Range (ATR) 0.10 0.54
MACD -0.01 0.03
Stochastic Oscillator 4.90 55.88

Price Performance

Historical Comparison
WALD
CRBP

About WALD Waldencast plc

Waldencast PLC is a beauty and wellness operating platform. The company is organized into two reportable segments namely Obagi Skincare and Milk Makeup. The company generates the majority of its revenue from the Obagi Medical segment. The Obagi Medical segment is engaged in developing, marketing, and selling skin health products. The Milk Makeup segment includes developing, marketing, and selling cosmetics, skincare, and other beauty products. Geographically the company generates the majority of its revenue from North America region.

About CRBP Corbus Pharmaceuticals Holdings Inc.

Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.

Share on Social Networks: